ANGLE Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andrew David Newland

Chief Executive Officer (CEO)

UK£281.0k

Compensación total

Porcentaje del salario del CEO	95.7%
Permanencia del CEO	20.7yrs
Participación del CEO	2.3%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	9.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew David Newland en comparación con los beneficios de ANGLE?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-UK£18m
Mar 31 2024	n/a	n/a	-UK£19m
Dec 31 2023	UK£281k	UK£269k	-UK£20m
Sep 30 2023	n/a	n/a	-UK£21m
Jun 30 2023	n/a	n/a	-UK£22m
Mar 31 2023	n/a	n/a	-UK£22m
Dec 31 2022	UK£264k	UK£253k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£19m
Jun 30 2022	n/a	n/a	-UK£17m
Mar 31 2022	n/a	n/a	-UK£16m
Dec 31 2021	UK£446k	UK£242k	-UK£15m
Sep 30 2021	n/a	n/a	-UK£15m
Jun 30 2021	n/a	n/a	-UK£16m
Mar 31 2021	n/a	n/a	-UK£14m
Dec 31 2020	UK£392k	UK£240k	-UK£12m
Jun 30 2020	n/a	n/a	-UK£10m
Mar 31 2020	n/a	n/a	-UK£11m
Dec 31 2019	UK£244k	UK£160k	-UK£11m
Oct 31 2019	n/a	n/a	-UK£10m
Jul 31 2019	n/a	n/a	-UK£9m
Apr 30 2019	n/a	n/a	-UK£9m
Jan 31 2019	n/a	n/a	-UK£9m
Oct 31 2018	n/a	n/a	-UK£8m
Jul 31 2018	n/a	n/a	-UK£8m
Apr 30 2018	UK£336k	UK£229k	-UK£8m

Compensación vs. Mercado: La compensación total ($USD352.48K) de Andrew David está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD354.57K).

Compensación vs. Ingresos: La compensación de Andrew David ha aumentado mientras la empresa no es rentable.

CEO

Andrew David Newland (63 yo)

20.7yrs

Permanencia

UK£281,000

Compensación

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew David Newland	Founder	no data	UK£281.00k	2.26% £ 730.5k
Ian Griffiths	CFO, Finance Director	7.4yrs	UK£180.00k	0.39% £ 127.1k
Karen Miller	Chief Scientific Officer	1.8yrs	sin datos	sin datos
Andrew Holder	Head of Investor Relations	no data	sin datos	sin datos
Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	1.1yrs	sin datos	sin datos
Brett Swansiger	Chief Commercial Officer	1.8yrs	sin datos	sin datos

1.8yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AGL no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew David Newland	Founder	20.7yrs	UK£281.00k	2.26% £ 730.5k
Ian Griffiths	CFO, Finance Director	20.7yrs	UK£180.00k	0.39% £ 127.1k
Harold Swerdlow	Member of Scientific Advisory Board	no data	sin datos	sin datos
Juliet Thompson	Non-Executive Director	1.8yrs	UK£48.00k	sin datos
Brian Howlett	Non-Executive & Senior Independent Director	11.8yrs	UK£27.00k	0.0031% £ 999.8
Jan Groen	Independent Non-Executive Chairman	6yrs	UK£50.00k	sin datos
James Reuben	Member of Scientific Advisory Board	9.4yrs	sin datos	sin datos
Daniel Danila	Member of Scientific Advisory Board	9.3yrs	sin datos	sin datos
Greg Shaw	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joseph Eid	Non-Executive Director	1.8yrs	UK£40.00k	sin datos

9.4yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de AGL se considera experimentada (9.4 años de antigüedad promedio).

ANGLE Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

ANGLE plc, Annual General Meeting, Jun 26, 2024

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

Recent updates

Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR

New major risk - Share price stability

Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer